This patient risk-assessment machine learning algorithm predicts patient response to cardiac resynchronization therapy (CRT) intervention enabling more informed selection criteria and improved rates of therapy success. Approximately 90,000 patients receive cardiac resynchronization therapy per year, with only 50% of that population benefitting. This directly results from the uncertainties surrounding which patients will actually benefit from the procedure. Providing insights into…
Inventor: Will Richardson, Anamul Haque, William Douglas Stubbs Jr.
Clemson University researchers have developed an in vitro
myocardial therapy screening platform possessing superior
physiological relevance that enables clinically translatable metrics
for therapy efficacy and cardiotoxicity evaluation.
Inventor: William Richardson, Samuel Coeyman, Jonathan G. Heywood
Clemson University researchers have developed an anti-biofouling approach that can inactivate bacteria without introducing chemicals into the feed water and without pausing operation of the membrane treatment process.
Inventor: Ezra Cates
Clemson University researchers have developed a new family of modified small molecules that include bisbenzimidazole derivatives as antimicrobials and topoisomerase inhibitors.
Inventor: Dev Arya, Nihar Ranjan, Fenfei Leng
Because of the rising role of biopharmaceuticals, there is increasing need in the market for specialized phases to isolate specific proteins, Clemson researchers have patented a technology that has the potential to fill this need in the market.
Inventor: Richard Kenneth Marcus, Kenneth Christensen